global
pandem
howev
specif
antivir
drug
still
unavail
pateint
manag
antiinflammatori
effect
reduc
increas
lymphocyt
appear
lmwh
use
potenti
therapeut
drug
treatment
pave
way
subsequ
wellcontrol
clinic
trial
multipl
complementari
lymphopenia
inflammatori
cytokin
storm
typic
abnorm
observ
highli
pathogen
coronaviru
infect
sar
mer
believ
associ
diseas
sever
sever
clinic
studi
reveal
cytokin
storm
import
mechan
underli
diseas
exacerb
death
patient
particularli
level
sever
ill
patient
significantli
higher
mild
case
one
core
cytokin
consist
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
found
elev
plasma
patient
cytokin
storm
contribut
mani
key
symptom
cytokin
storm
vascular
leakag
activ
complement
coagul
cascad
induc
dissemin
intravascular
coagul
dic
reduc
level
activ
may
contribut
prevent
even
revers
cytokin
storm
syndrom
therebi
improv
condit
patient
substanti
studi
report
low
molecular
weight
heparin
lmwh
variou
nonanticoagul
properti
play
antiinflammatori
role
reduc
releas
howev
antiinflammatori
effect
lmwh
current
unknown
analyz
reliev
effect
lmwh
patient
retrospect
cohort
studi
demonstr
first
time
signific
benifi
effect
lmwh
control
ctytokin
storm
approach
believ
delay
diseas
progress
patient
strongli
encurag
wellcontrol
clinic
practic
fig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
evalu
use
ttest
measur
data
chisquar
test
count
data
kruskalw
nonparametr
test
group
independ
sampl
within
group
relat
sampl
differ
p
consid
statist
signific
gener
characterist
patient
shown
tabl
lmwh
group
consist
male
eight
femal
age
year
median
age
year
control
group
consist
male
seven
femal
age
year
median
age
year
signific
differ
comorbid
hypertens
diabet
cardiovascular
diseas
cancer
two
group
similarli
signific
differ
coronaviru
pneumonia
onset
symptom
includ
fever
bodi
temperatur
cough
sputum
chest
distress
asthma
myalgia
fatigu
anorexia
diarrhea
nausea
vomit
similarli
signific
differ
antivir
treatment
two
group
result
indic
gener
characterist
two
group
patient
consist
compar
lmwh
effect
durat
convers
neg
length
patient
hospit
shown
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
lmwh
group
lmwh
treatment
significantli
differ
control
group
shown
fig
level
fibrinogen
degrad
product
fdp
lmwh
group
significantli
higher
compar
control
group
treatment
signific
differ
fdp
level
lmwh
control
group
lmwh
treatment
lmwh
group
fdp
level
significantli
reduc
lmwh
treatment
chang
fdp
level
patient
lmwh
group
lmwh
treatment
significantli
differ
control
group
howev
signific
differ
fibrinogen
fib
fig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
determin
whether
ddimer
associ
sever
therefor
present
studi
consid
paramet
evalu
index
diseas
progress
averag
valu
ddimer
fdp
treatment
higher
lmwh
group
control
group
p
p
therefor
lmwh
appli
trial
retrospect
analysi
interven
type
treatment
given
patient
infer
purpos
medic
lmwh
group
improv
hypercoagul
ddimer
fdp
consid
factor
design
patient
diseas
progress
level
effect
subsequ
analysi
result
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
statist
signific
differ
crp
level
group
indic
lmwh
treatment
effect
paramet
notabl
lym
higher
lmwh
group
compar
control
group
p
consist
result
derhaschnig
et
al
suggest
lmwh
increas
lym
patient
therebi
improv
condit
furthermor
report
proinflammatori
cytokin
induc
lymphopenia
henc
decreas
fig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
convent
antivir
treatment
regimen
lmwh
improv
hypercoagul
inhibit
releas
attenu
biolog
activ
potenti
antivir
effect
help
delay
block
inflammatori
cytokin
storm
lmwh
increas
lym
patient
multipl
effect
lmwh
encourag
applic
treatment
patient
patient
data
express
mean
standard
deviat
sd
n
vs
vs
p
aa
p
aaa
p
vs
vs
b
p
bb
p
bbb
p
vs
c
p
cc
p
ccc
p
control
group
indic
admiss
control
group
indic
discharg
control
group
chang
indic
hospit
lmwh
group
indic
lmwh
treatment
lmwh
group
indic
lmwh
treatment
lmwh
group
chang
indic
lmwh
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
